PENICILLAMINE Drug Patent Profile

Which patents cover Penicillamine, and what generic alternatives are available?

Penicillamine is a drug marketed by Apotex, Breckenridge, Dr Reddys, Granules, Invagen Pharms, Navinta Llc, Ph Health, Watson Labs Inc, Lupin Ltd, and Teva Pharms Usa. and is included in eleven NDAs.

The generic ingredient in PENICILLAMINE is penicillamine. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the penicillamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Penicillamine

A generic version of PENICILLAMINE was approved as penicillamine by WATSON LABS INC on June 24^th, 2019.

Summary for PENICILLAMINE

US Patents:	0
Applicants:	10
NDAs:	11
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	19
Patent Applications:	4,267
Drug Prices:	Drug price information for PENICILLAMINE
What excipients (inactive ingredients) are in PENICILLAMINE?	PENICILLAMINE excipients list
DailyMed Link:	PENICILLAMINE at DailyMed

See drug prices for PENICILLAMINE

Recent Clinical Trials for PENICILLAMINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Muhammad Zark	PHASE2
Nanfang Hospital, Southern Medical University	Phase 2
Narowal Medical College	NA

See all PENICILLAMINE clinical trials

Pharmacology for PENICILLAMINE

Drug Class

Antirheumatic Agent

Medical Subject Heading (MeSH) Categories for PENICILLAMINE

Antidotes

Antirheumatic Agents

Chelating Agents

Anatomical Therapeutic Chemical (ATC) Classes for PENICILLAMINE

M01CC	Penicillamine and similar agents
M01C	SPECIFIC ANTIRHEUMATIC AGENTS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

US Patents and Regulatory Information for PENICILLAMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	PENICILLAMINE	penicillamine	CAPSULE;ORAL	213310-001	Apr 28, 2020		DISCN	No	No
Ph Health	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211231-001	Dec 23, 2019	AB	RX	No	No
Granules	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211735-001	Dec 2, 2020	AB	RX	No	No
Watson Labs Inc	PENICILLAMINE	penicillamine	CAPSULE;ORAL	210976-001	Jun 24, 2019	AB	RX	No	No
Breckenridge	PENICILLAMINE	penicillamine	CAPSULE;ORAL	215409-001	Aug 23, 2021	AB	RX	No	No
Dr Reddys	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211867-001	Aug 4, 2020	AB	RX	No	No
Navinta Llc	PENICILLAMINE	penicillamine	CAPSULE;ORAL	214363-001	Oct 8, 2021	AB	RX	No	No

Market Dynamics and Financial Trajectory for Penicillamine

Last updated: February 19, 2026

What Is Penicillamine and Its Approved Uses?

Penicillamine is a chelating agent approved by the U.S. Food and Drug Administration (FDA) primarily for the treatment of Wilson’s disease, a genetic disorder causing copper accumulation. It is also prescribed for rheumatoid arthritis in some cases and for heavy metal poisoning, including lead and mercury toxicity.

Market Size and Growth Trends

Current Market Size

• The global penicillamine market was valued at approximately USD 200 million in 2022.
• The primary revenue generators are North America (approx. 50%), Europe (around 30%), and Asia-Pacific (roughly 15%).

Market Growth Drivers

• Rising prevalence of Wilson’s disease, which occurs in approximately 1 in 30,000 live births.
• Increased diagnosis and awareness of heavy metal poisoning.
• Off-label use in rheumatoid arthritis, though limited by availability of biologics.
• Growing healthcare infrastructure in emerging markets.

Estimated Compound Annual Growth Rate (CAGR)

• From 2023 to 2030, the market is projected to grow at a CAGR of 3-4%, driven by increased diagnosis and healthcare spending.

Competitive Landscape and Key Players

Major Manufacturers

Company	Product Availability	Market Share (Estimated)	Notes
Alkem Laboratories Ltd.	Penicillamine (India)	~30%	Key in India, expanding in Asia
Cipla Ltd.	Penicillamine	~20%	Focus on generics, global reach
Others (Sandoz, Mylan)	Various	~50%	Generic manufacturers, limited proprietary rights

Patent and Regulatory Status

• Penicillamine is off-patent since the 1980s.
• Regulatory approvals are maintained for specific formulations; no recent patent filings or exclusivity rights are in place, leading to a highly commoditized market.

Pricing and Reimbursement

• Average wholesale prices per 250 mg capsule: USD 0.50 - 0.80.
• Reimbursement varies by country; higher in North America and Western Europe.
• Price erosion due to generic competition influences profitability.

Supply Chain Dynamics

• Raw materials are primarily produced in China and India.
• There is reliance on imported raw materials, creating supply chain vulnerabilities.
• Quality control concerns impact manufacturing consistency.

Financial Trajectory and Investment Outlook

Revenue Generation

• Revenues are driven by volume sales rather than price premiums due to patent expiration.
• Fiscal periods with increased demand for Wilson's disease treatments or heavy metal poisoning cases tend to see revenue spikes.

R&D and Product Development

• Limited R&D activity given patent expirations and small market size.
• Focus is on manufacturing process improvements and supply chain efficiencies.

Future Investment Trends

• Small biotech and pharmaceutical firms may explore reformulations or combination therapies.
• No significant pipeline developments for new chemical entities related to penicillamine.

Regulatory and Market Challenges

• Replacement by newer, targeted therapies for autoimmune and metal poisoning indications.
• Regulatory scrutiny on manufacturing practices.
• Price competition from generics restricts profit margins.

Summary

The penicillamine market is a small, mature segment with steady but slow growth. It faces pricing pressure, limited innovation, and supply chain risks. Major revenue is derived from generic sales in established markets, with emerging markets offering growth opportunities. Limited R&D investment reduces the likelihood of significant breakthrough developments.

---

Key Takeaways

• The global penicillamine market was valued at USD 200 million in 2022, with a CAGR of 3-4% projected through 2030.
• Market growth is driven by increased diagnosis of Wilson’s disease and heavy metal poisoning.
• The market is highly competitive, dominated by generics from companies like Alkem and Cipla.
• Price erosion and supply chain risks challenge profitability.
• Limited pipeline activity and patent expirations restrict innovation.

---

FAQs

1. What factors influence penicillamine market growth?
Diagnosis rates of Wilson’s disease, heavy metal poisoning prevalence, healthcare spending, and generic market expansion.

2. Are there patented formulations of penicillamine?
No; the drug is off-patent, leading to a competitive, low-margin market environment.

3. Which regions dominate penicillamine sales?
North America accounts for about half of total sales, followed by Europe, with potential in Asia-Pacific.

4. What are the main challenges facing the penicillamine market?
Price competition from generics, supply chain vulnerabilities, and obsolescence due to newer therapies.

5. Is there ongoing research to improve or replace penicillamine?
Limited R&D; focus is primarily on process improvements. Few new products are in pipeline.

---

References

1. MarketWatch. (2023). Global Penicillamine Market Size, Share & Trends Analysis. [Online] Available at: https://www.marketwatch.com/market-data
2. U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
3. Global Market Insights. (2022). Chelation Therapy Market Trends and Opportunities.
4. World Health Organization. (2021). Wilson’s Disease: Epidemiology and Diagnosis.